Stock Chart
ACAD
Type: SELL growth_1yr
Strike: $20
Premium: $5.20
Expiry: Jan 15, 2027
Target: $19
Score: -100
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About ACAD - Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used …
Key Statistics
More ACAD Analysis
This ACAD stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track ACAD's price movements with trendlines, gamma walls, and key support/resistance levels.